ArticleBMC surgery2026
Clinical efficacy of MWA via the caudal‒cranial direction puncture pathway for small hepatocellular carcinoma at the hepatic dome: 3 years of follow-up.
Article in BMC surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the clinical efficacy of microwave ablation (MWA) for small hepatocellular carcinoma (HCC) located at the hepatic dome via the caudal‒cranial direction puncture pathway(CCDPP) within the coronal or sagittal plane under computed tomography (CT) guidance.
methodsA retrospective analysis was conducted to analyze data from 29 patients with HCC located at the hepatic dome who underwent CT-guided MWA from March 2019 to November 2024. The puncture path of the microwave antenna during ablation is from caudal to cranial direction within the coronal or sagittal planes reconstructed via multislice spiral CT. Baseline patient data were collected, and outcomes, including the puncture technique success rate, ablation success rate, and incidence of complications, etc., were observed. Kaplan‒Meier survival curve analysis was used to calculate the disease-free survival (DFS) and overall survival (OS) rates of all patients.
resultsA total of 29 lesions in 29 patients were ablated and the mean timor size is 25.5 ± 11.0 mm. The puncture technique success rate and ablation success rates were both 100%, and no serious complications occurred. One month post-MWA, enhanced abdominal CT or MRI scans revealed complete ablation in 96.6% of all patients, whereas 3.4% (1/29) had incomplete ablation, necessitating additional MWA treatment. By the cutoff of follow-up, the mean follow-up time for all patients was 26.03 ± 17.98 months. The local tumor progression rate was 17.2%, and the 1-, 2-, and 3-year disease-free survival rates were 88.1%, 74.2%, and 74.2%, respectively. The 1-, 2-, and 3-year overall survival rates were 91.8%, 72.4%, and 72.4%, respectively. Further subgroup analysis did not find any statistically significant differences whether administrating TACE before ablation or not and the distance between the tumor and the diaphragm less than 5 mm or not.
conclusionMicrowave ablation with the CCDPP used in the puncture process could be preliminarily revealed to be safe, feasible, and effective, with acceptable oncological midterm outcomes for the treatment of small HCC lesions in the hepatic dome. Further research is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.